Cord Pilot Trial

Immediate cord clamping versus deferred cord clamping for preterm birth before 32 weeks gestation: a pilot randomised trial

Final version 3 dated 29 January 2014

MAIN SPONSOR: Nottingham University Hospitals NHS Trust
FUNDER: NIHR
TRIAL COORDINATION CENTRE: Nottingham Clinical Trials Unit
NRES reference: 12/EM/0283
NRES Committee: NRES Committee East Midlands – Nottingham 2
ISRCTN: ISRCTN21456601

Protocol authorised by:

<table>
<thead>
<tr>
<th>Name &amp; Role</th>
<th>Date</th>
<th>Signature</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prof Lelia Duley</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chief Investigator</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Prof Alan Montgomery</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Statistician</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Key Contacts

**Trial Management Group**

**Chief Investigator:** Prof Lelia Duley  
Nottingham Clinical Trials Unit  
Nottingham Health Science Partners (NHSP)  
C Floor, South Block, Queens Medical Centre, Nottingham, NG7 2UH

**Statistician:** Prof Alan Montgomery  
Nottingham Clinical Trials Unit  
Nottingham Health Science Partners (NHSP)  
C Floor, South Block, Queens Medical Centre, Nottingham, NG7 2UH

**Trial Management:** Nottingham Clinical Trials Unit

**Co-investigators:**
- Ms Jane Abbott: Service User Advocate, BLISS, special care baby charity
- Ms Gillian Gyte: Service User Advocate, National Childbirth Trust
- Dr Sam Oddie: Consultant, Bradford Teaching Hospitals NHS Foundation Trust
- Prof James Thornton: Consultant, University of Nottingham
- Dr Jon Dorling: Consultant, University of Nottingham

**Trial Coordination Centre**

For general queries, supply of trial documentation, and collection of data, please contact:

**Trial manager:**

**Address:**  
Nottingham Clinical Trials Unit, UKCRC 26  
Nottingham Health Science Partners (NHSP)  
C Floor, South Block, Queens Medical Centre, Nottingham, NG7 2UH

**Telephone:** 0115 8844936  
**E-mail:** angela.pushpa-rajah@nottingham.ac.uk  
**Fax:** 0115 9194309  
**Web address:** http://www.nottingham.ac.uk/nctu/trials/pregnancy-and-childbirth.aspx

**Clinical Queries**

Clinical queries should be directed to Prof Lelia Duley.

**Sponsor**

Nottingham University Hospitals NHS Trust is the main research sponsor for this trial. For further information regarding the sponsorship conditions, please contact:

**Research Governance Manager at:**

**Research & Development**

Nottingham University Hospitals NHS Trust  
Nottingham Health Science Partners (NHSP)  
C Floor, South Block, Queens Medical Centre, Nottingham, NG7 2UH

**Telephone:** 0115 9709049  
**Fax** 0115 8493295

**Funder**

NIHR Programme Grant for Applied Research

This protocol describes the **Immediate cord clamping versus deferred cord clamping for preterm birth before 32 weeks gestation: a pilot randomised trial** and provides information about procedures for entering participants. Every care was taken in its drafting, but corrections or amendments may be necessary. These will be circulated to investigators in the trial. Problems relating to this trial should be referred, in the first instance, to the Chief Investigator.

This trial will adhere to the principles outlined in the NHS Research Governance Framework for Health and Social Care (2nd edition). It will be conducted in compliance with the protocol, the Data Protection Act and other regulatory requirements as appropriate.
### Amendment History

**Amendment No. SA01**

<table>
<thead>
<tr>
<th>Page</th>
<th>Section</th>
<th>Previous wording</th>
<th>New wording</th>
</tr>
</thead>
</table>
| Title | This change has been implemented throughout the document. | Preterm Cord Clamping Trial  
Immediate cord clamping with neonatal care at the roomside, versus deferred cord clamping with neonatal care at the bedside for preterm birth before 32 weeks gestation: a pilot randomised trial | Cord Pilot Trial  
Immediate cord clamping versus deferred cord clamping for preterm birth before 32 weeks gestation: a pilot randomised trial |
| Throughout the protocol | The wording has changed in the following sections  
Trial summary,  
Summary,  
Introduction (*Initial care at birth for very preterm infants: at the bedside or at the roomside*)  
Objectives,  
Pilot trial description,  
Pilot trial interventions  
Treatment of participants | At the collaborators meeting it became clear that some sites would want to offer care at the bedside to women with immediate clamping – as this is now part of their standard care. The protocol has been reworded to reflect this shift in practice. |
| Randomisation | 3.4 | Women who are eligible and have agreed to participate will be randomised using sealed consecutively numbered packs. Each maternity unit will keep a central log of all packs. On the front of the pack will be a check list of the inclusion and exclusion criteria, and space to record the date, time, woman’s initials, her data of birth, and her estimated gestation (or estimated gestation). Once this information is complete, the woman will be considered to be randomised, even if the pack is not opened. | Women who are eligible and have agreed to participate will be randomised using sealed consecutively numbered opaque envelopes. Envelopes will be in a Cord Trial ringbinder, and removed in consecutive order by tearing at the punch holes. Each maternity unit will keep a central log of all envelopes. On the front of the envelope will be a reminder to check eligibility criteria, and space to record the date, time, woman’s initials, her data of birth, and her estimated gestation. Once this information is complete, the woman will be considered to be randomised, even if the pack is not opened.  
Inside the envelope will be a card with the allocated intervention, two |
Inside the pack will be a card with the allocated intervention, two stickers (one each for the woman’s and baby’s notes), a sticker for the consent form, and two booklets of data collection forms, one for the woman and one for the baby. Date and time of birth of the baby and time of cord clamping will be recorded on the front of the pack, and later transferred to the woman’s booklet.

<table>
<thead>
<tr>
<th>Source data</th>
<th>3.11</th>
<th>Information required for randomisation will be recorded on the randomisation pack at trial entry (see 3.4 above).</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Information required at randomisation will be recorded on the randomisation envelope at trial entry (see 3.4 above).</td>
</tr>
<tr>
<td></td>
<td></td>
<td>To facilitate maintaining contact with the families, women will also be asked to provide contact details with other relevant relatives, for example grandparents.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Trial entry and recruitment</th>
<th>5.1</th>
<th>More clarification has been included</th>
</tr>
</thead>
</table>

**Substantial Amendment 03**

<table>
<thead>
<tr>
<th>Page</th>
<th>Section</th>
<th>Previous wording</th>
<th>New wording</th>
</tr>
</thead>
<tbody>
<tr>
<td>Trial Summary</td>
<td>Duration</td>
<td>Recruitment is for 12 months. Follow up for the women is for 12 months, and for the children until age two years (corrected for gestation at birth)</td>
<td>Recruitment to the initial feasibility phase of the pilot trial is for 12 months but will be extended after this phase until 31 December 2014. Follow up for the women is for 12 months, and for the children until age two years (corrected for gestation at birth)</td>
</tr>
<tr>
<td>Table 1</td>
<td>Child Age 2 years</td>
<td>Ages and Stages Questionnaire (ASQ) added to table for the 2 year follow up. PARCA_R and Bayley III assessment for families recruited from 01 March 2013 to 28 February 2014 only.</td>
<td>The target sample size for the initial feasibility phase is 100-110 mother-infant pairs in 8 sites.</td>
</tr>
<tr>
<td>Summary</td>
<td>The sample size is 100-110 mother-infant pairs.</td>
<td>The target sample size for the initial feasibility phase is 100-110 mother-infant pairs in 8 sites.</td>
<td></td>
</tr>
<tr>
<td>Pilot Trial Description</td>
<td>3.3</td>
<td>The aim is to recruit at least 100-110 women in at least eight maternity units. Recruitment will be for 12</td>
<td>The aim is to recruit at least 100-110 women for the initial feasibility phase in at least eight maternity units. Recruitment to the initial feasibility phase of the pilot trial will be for 12</td>
</tr>
</tbody>
</table>
months. Follow up for the women is for 12 months, and follow up for the children is until age two years (corrected for gestation at birth).

### Duration of Participation

<table>
<thead>
<tr>
<th>3.7</th>
<th>Recruitment to the pilot trial will be for 12 months. Follow up for the women will be for 12 months, and for the children until they are two years old, corrected for gestation at birth. The end of the trial is defined as the “last child’s neurodevelopment assessment”.</th>
</tr>
</thead>
<tbody>
<tr>
<td>3.7</td>
<td>Follow up for the women will be for 12 months, and for the children until they are two years old, corrected for gestation at birth. The end of the trial is defined as the “last child’s 2 year Follow Up”.</td>
</tr>
</tbody>
</table>

### Source Data

<table>
<thead>
<tr>
<th>3.11</th>
<th>Outcome data for the women will be the medical notes, and the pilot trial questionnaires. For the children, outcome data will come from the medical notes, the Parent Report of Children’s Abilities – Revised (PARCA-R) and the Bayley Scales of Infant Development.</th>
</tr>
</thead>
<tbody>
<tr>
<td>3.11</td>
<td>Outcome data for the women will be the medical notes, and the pilot trial questionnaires. For the children, outcome data will come from the medical notes, and the Ages and Stages Questionnaire (ASQ). For families recruited between 01 March 2013 – 28 February 2014, outcome data will also be collected from the Parent Report of Children’s Abilities – Revised (PARCA-R) and the Bayley Scales of Infant Development.</td>
</tr>
</tbody>
</table>

### Participant follow-up

<table>
<thead>
<tr>
<th>5.3</th>
<th>Six weeks after the birth, women will also be asked to complete a brief questionnaire.</th>
</tr>
</thead>
<tbody>
<tr>
<td>5.3</td>
<td>Within 2-3 months after the birth, women will also be asked to complete a brief questionnaire.</td>
</tr>
</tbody>
</table>

### Participant follow-up

<table>
<thead>
<tr>
<th>5.3</th>
<th>At the child’s second birthday, corrected for gestation at birth, the family will be contacted to arrange a neurodevelopment assessment for the child. Four weeks before this assessment, the family will be sent the Parent Report of Children’s Abilities – Revised (PARCA-R) by post, and asked to complete and return this before the assessment. The neurodevelopment assessment will use the Bayley Scales of Infant Development III, and will be conducted by a trained practitioner either at home or in the clinic, whichever is preferred by the family. The assessment usually takes between one and a half and</th>
</tr>
</thead>
<tbody>
<tr>
<td>5.3</td>
<td>At the child’s second birthday, corrected for gestation at birth, the family will be contacted for the 2 year follow up. Families recruited into the trial between 01 March 2013 and 28 February 2014, will be contacted to arrange a neurodevelopment assessment for their child. Four weeks before the child’s second birthday, corrected for gestation at birth, the family will be sent the Ages and Stages Questionnaire (ASQ) by post, and asked to complete and return this before the assessment. A stamped addressed envelope will be provided to return the questionnaire. The neurodevelopment assessment will use the Bayley Scales of Infant Development III, and will be conducted by a trained practitioner either at home or in the clinic, whichever is preferred by the family. The assessment usually takes between one and a half and</td>
</tr>
</tbody>
</table>
preferred by the family. The assessment usually takes between one and a half and two hours. If the child dies before their first birthday, the mother will remain in follow up as long as she is in agreement with this.

In October 2013 it was agreed within the CORD Pilot Trial DMC and TSC meetings that recruitment to the pilot trial should be extended to run into the start of the main trial. This would allow clinicians in the current eight pilot study sites to avoid losing equipoise regarding the timing of umbilical cord clamping. Recruitment will be extended from 01 March 2014 until 31 December 2014, by which time a decision regarding the funding for the main trial should be definite.

| Estimated Sample Size | 7.1 |
| References | 15 |

Table of Contents

Key Contacts ........................................................................................................................................ 2
Amendment History ............................................................................................................................ 3
Glossary of Abbreviations .................................................................................................................. 9
Keywords ................................................................................................................................................ 9
Trial Summary ........................................................................................................................................ 10
Reference diagrams ............................................................................................................................... 11
  Flowchart 1. Participant flow ................................................................................................................ 11
  Flowchart 2. Guidance for consent ........................................................................................................ 12
  Table 1. Study assessments .................................................................................................................. 13

Summary ................................................................................................................................................ 14

1  INTRODUCTION .................................................................................................................................. 15
   1.1 Background ........................................................................................................................................ 15
   1.2 Why a trial is needed now .................................................................................................................. 17

2  PILOT TRIAL OBJECTIVES AND PURPOSE .............................................................................. 18
   2.1 Objectives ........................................................................................................................................ 18

3  TRIAL DESIGN ..................................................................................................................................... 18
   3.1 Main trial outcomes ........................................................................................................................... 18
   3.2 Pilot trial outcomes ............................................................................................................................ 18
   3.3 Pilot trial description .......................................................................................................................... 19
   3.4 Randomisation ................................................................................................................................... 19
   3.5 Minimisation of bias ........................................................................................................................... 19
   3.6 Pilot trial interventions ....................................................................................................................... 19
   3.7 Duration of participation .................................................................................................................... 20
   3.8 Stop-go criteria for proceeding to the main trial .............................................................................. 20
   3.9 Compliance with interventions .......................................................................................................... 20
   3.10 Maintenance of randomisation codes and procedures for breaking code ................................... 20
   3.11 Source data ...................................................................................................................................... 20

4  SELECTION AND WITHDRAWAL OF TRIAL PARTICIPANTS ....................................................... 21
   4.1 Inclusion criteria .............................................................................................................................. 21
   4.2 Exclusion criteria ............................................................................................................................. 21
   4.3 Participants who withdraw ............................................................................................................... 21
   4.4 Managing and replacing participants who withdraw from the trial early .................................... 21

5  TRIAL PROCEDURES .......................................................................................................................... 22
   5.1 Trial entry and recruitment .............................................................................................................. 22
   5.2 Treatment of participants ............................................................................................................... 22
   5.3 Participant follow-up ....................................................................................................................... 23

6  ADVERSE EVENTS ............................................................................................................................... 24
   6.1 Serious adverse events ..................................................................................................................... 24

7  STATISTICS AND DATA ANALYSIS ............................................................................................. 24
   7.1 Estimated sample size ...................................................................................................................... 24
   7.2 Analysis plan .................................................................................................................................... 25

8  DIRECT ACCESS TO SOURCE DATA/DOCUMENTS ................................................................... 26

9  QUALITY CONTROL AND QUALITY ASSURANCE PROCEDURES ....................................... 26
   9.1 Site start-up and training .................................................................................................................. 26
   9.2 Data collection and processing ........................................................................................................ 26
   9.3 Monitoring ....................................................................................................................................... 26
9.4 Archiving

10 TRIAL MANAGEMENT
10.1 Trial Management Group
10.2 Trial Steering Committee
10.3 Data Monitoring Committee
10.4 Principal investigators

11 ETHICS
11.1 Approvals
11.2 Participant confidentiality

12 DATA HANDLING AND RECORD KEEPING

13 FINANCING AND INDEMNITY

14 PUBLICATION POLICY
14.1 Reporting, dissemination and notification of the results
14.2 Policy for publication and authorship

15 REFERENCES

Appendix 1. Principal Investigator Declaration
Glossary of Abbreviations

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>AW</td>
<td>Antenatal Ward</td>
</tr>
<tr>
<td>CRF</td>
<td>Case Record Form</td>
</tr>
<tr>
<td>DMC</td>
<td>Data Monitoring Committee</td>
</tr>
<tr>
<td>DS</td>
<td>Delivery Suite</td>
</tr>
<tr>
<td>GCP</td>
<td>Good Clinical Practice</td>
</tr>
<tr>
<td>NHS</td>
<td>National Health Service</td>
</tr>
<tr>
<td>R&amp;D</td>
<td>Research and Development Department</td>
</tr>
<tr>
<td>SAE</td>
<td>Serious Adverse Event</td>
</tr>
<tr>
<td>TSC</td>
<td>Trial Steering Committee</td>
</tr>
</tbody>
</table>

Keywords

Cord clamping, placental transfusion, preterm birth, feasibility study, randomised trial, neurodevelopment
## Trial Summary

<table>
<thead>
<tr>
<th><strong>TITLE</strong></th>
<th>Immediate cord clamping versus deferred cord clamping for preterm birth before 32 weeks gestation: a pilot randomised trial</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>DESIGN</strong></td>
<td>Randomised trial</td>
</tr>
<tr>
<td><strong>AIMS</strong></td>
<td>To test the feasibility of conducting a large UK trial to assess the effect of timing of cord clamping for preterm birth before 32 weeks gestation on disability-free survival at two years of age.</td>
</tr>
</tbody>
</table>
| **OUTCOME MEASURES** | For this feasibility pilot trial:  
1. number of women recruited in each hospital  
2. proportion of potentially eligible women recruited  
3. reasons for non-recruitment (medical, parental, logistic, other)  
4. spectrum of gestational age and neonatal outcome among recruits  
5. compliance with the trial interventions, and reasons for non-compliance  
6. completeness of data collection for main outcomes  
7. views of women and their partners on recruitment, randomisation and the interventions  
8. proportion lost to follow up after discharge from hospital, and reasons for loss to follow up |
| **POPULATION** | Women having a livebirth before 32 weeks gestation. |
| **ELIGIBILITY** | Women will be eligible for the study if they are expected to have a livebirth before 32 weeks gestation. Exclusion criteria are:  
- Monochorionic twins diagnosed by ultrasound  
- Triplets, or higher order, multiple pregnancy  
- Known congenital malformation |
| **DURATION** | Recruitment to the initial feasibility phase of the pilot trial is for 12 months but will be extended after this phase until 31 December 2014. Follow up for the women is for 12 months, and for the children until age two years (corrected for gestation at birth) |
Reference diagrams

Flowchart 1. Participant flow

Woman in maternity unit and at risk of preterm birth

Check eligibility

Woman gives consent
(see flowchart 2)

Not eligible
No further contact

Birth imminent
(preparing for caesarean section, or in established labour)

Check eligibility

Eligibility confirmed

RANDOMISATION

Immediate cord clamping
- clamping within 20 seconds
- neonatal care at the roomside/bedside

Deferred cord clamping
- clamping after at least 2 minutes
- neonatal care at the bedside

Women: outcome at discharge

Women: follow-up at 12 months

Children: outcome at discharge

Children: follow up at age 2 years
(corrected for gestation at birth)
Flowchart 2. Guidance for consent

Information about the trial available to women in antenatal clinics and antenatal wards

Woman admitted to maternity unit and meets eligibility criteria

Woman gives written informed consent

Birth imminent (preparing for caesarean section, or in established labour)

Check woman’s eligibility
- continues to meet eligibility criteria
- oral confirmation of agreement to participate

Woman gives oral assent
- if insufficient time for written informed consent, because the woman is in established labour or having an emergency caesarean section, assent may be oral*

Randomisation

* Women will be approached to give oral assent in established labour or at emergency caesarean section only if the attending clinicians consider it appropriate. Women will not be approached if there is insufficient time to give a brief oral summary of the trial, or they do not speak fluent English and no translator is available. How long will be required for oral assent will depend on factors such as how much the woman already knows about the study, and her knowledge and wishes about care during the third stage. If the woman does not give oral assent she will not be recruited.

If oral assent for recruitment is given:
- Women will be approached before discharge from hospital to give written consent to participation in follow up and access to their data
- Chief Investigator notified within 15 days, and monitoring by Trial Steering Committee
Table 1. Study assessments

<table>
<thead>
<tr>
<th>Assessments</th>
<th>Screening +/- consent</th>
<th>Delivery Suite</th>
<th>Discharge of woman</th>
<th>6 weeks after birth</th>
<th>Discharge of baby</th>
<th>12 months after birth</th>
<th>Child age 2 years (corrected)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Woman eligibility screening</td>
<td>AW or DS</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Woman consent</td>
<td>AW or DS</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Woman randomisation</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Intervention to woman/baby</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Outcomes for women**
- Blood loss at birth
- Time of delivery of placenta
- Need for blood transfusion
- Hospital Anxiety and Depression Scale (HADS)
- Satisfaction with care at birth
- Woman’s views about trial participation

**Outcomes for infants**
- Time to first feed
- Any breast feeding
- Age breastfeeding/breast milk expressing stopped
- Death
- Temperature on admission to SCBU
- Length of stay on SCBU
- Required phototherapy for jaundice
- Required exchange transfusion for jaundice
- Blood transfusion
- Intraventricular haemorrhage (grade 3-4)
- Periventricular leukomalacia
- Respiratory distress syndrome
- Chronic lung disease
- Necrotizing enterocolitis
- Ages and Stages Questionnaire (ASQ)
- Parent Report of Children’s Abilities (PARCA-R)*
- Bayley Scales of infant development III*

* For families recruited from 01 March 2013 to 28 February 2014 only
Summary

Preterm birth is the most important single determinant of adverse outcome in terms of: survival; quality of life; psychosocial and emotional impact on the family; and costs for health services. In the UK one in every 70 babies is born before 32 weeks (very preterm). These infants often need help with breathing, feeding, and other life support. Those who survive may spend months in hospital, and suffer ill health or disability in childhood. Even modest improvement for these children and their families would be important.

When a preterm infant is born, the cord is usually clamped immediately. Deferring cord clamping will allow blood flow between the placenta and baby to continue for a few minutes after birth. The net flow is known as ‘placental transfusion’. For preterm babies, placental transfusion may amount to up to one third of the baby’s potential blood volume, and may continue for 2-5 minutes. This period of continued blood flow may help the baby during the transition from fetal to neonatal circulation. The additional blood volume may help protect against some of the complications of being born too soon. The systematic review suggests deferring cord clamping may be beneficial, but more evidence is needed about effects on substantive measures of morbidity, mortality and disability-free survival.

At birth, neonatal care and stabilisation takes place on a resuscitaire. Traditionally, this is at the side of the room, or in an adjacent room. If cord clamping is deferred, this should not mean that neonatal care is deferred. For this study, we have developed strategies for providing neonatal care and stabilisation of the baby at the bedside. This allows the mother and her partner to share the first few moments of their baby’s life, a more family-centred approach than taking the baby to the side of the room immediately at birth.

A large randomised trial to compare the effects of a policy of immediate cord clamping rather than deferred clamping for very preterm birth on survival and neurodevelopment of the child at age two years is needed. This protocol is for a pilot trial to assess the feasibility of conducting such a trial in the UK. Outcomes for the pilot trial are measures of feasibility of recruitment and retention. The target sample size for the initial feasibility phase is 100-110 mother-infant pairs in 8 sites.
1 INTRODUCTION

1.1 Background

In the UK infant mortality (deaths in the first year of life) for babies born very preterm (before 32 weeks gestation) is 144/1000 live births, compared to 1.8/1000 for those born at term (38 to 41 weeks)[1]. Very preterm birth accounts for 1.4% of live births in the UK, but 51% of infant deaths[1]. For infants born before 28 weeks, duration of hospital stay is 85 times longer than for term births, and hospital inpatient costs are £15,000 higher; for those born at 28 to 31 weeks, it is 16 times and £12,000 respectively[2].

Morbidity amongst children born very preterm who survive is also high compared to those born at term. Of very preterm infants who survive, 5%-10% develop cerebral palsy and those without severe disability have a twofold or greater increased risk for developmental, cognitive, and behavioural difficulties[3, 4]. Of babies born before 28 weeks, a quarter of survivors have neurosensory disability, such as cerebral palsy, severe developmental delay, blindness or deafness.5 Surviving children have higher levels of dysfunction in a range of measures of cognition, behaviour and functioning[5], impairments which persist into adolescence and early adulthood[6, 7]. Teenagers and young adults born very preterm also report poorer physical abilities and more chronic ill health and functional limitation than their peers born at term, although self-reporting of health-related quality of life is similar[8, 9]. Prematurity and its sequelae have an enormous negative psychosocial and emotional impact on parents and families[5, 10]. Even modest improvement in outcome would be of substantial benefit; to the children, their families, and the NHS.

Placental transfusion

Placental transfusion is the transfer of blood between the placenta and the baby at birth. For term births, this blood flow is usually complete by two minutes, but may continue for up to five minutes. The mean volume of placental transfusion for term births is 100 ml, which is around 29 ml/kg birth weight and 36% of neonatal blood volume at birth[11]. For preterm births, placental transfusion may take longer[12], and is incomplete if the cord is clamped within 30-90 seconds[13]. This seems logical, as at term two-thirds of the feto-placental circulation is in the infant, whilst below 30 weeks gestation a greater proportion is in the placenta[14]. Also, the umbilical vein is smaller than at term, and uterine contraction less efficient. Cord clamping before placental transfusion is complete may restrict neonatal blood volume and red cell mass, and interrupt transition from the fetal to neonatal circulation.

As the baby is born, umbilical circulation slows and pulmonary vascular resistance falls, rapidly increasing pulmonary blood flow. This is the beginning of transition from the fetal to the neonatal circulation. For infants born too early, the mechanisms for these circulatory changes may not be fully developed and so may take longer. Continued flow in the umbilical vein and arteries at birth may be part of the physiological mechanisms assisting the baby as it makes the transition from fetal to neonatal circulation. Restricting this flow by immediate cord clamping may restrict the baby’s ability to deal with this transition. If there is insufficient circulating blood volume to fill the expanding pulmonary vasculature, an infant may compensate by reducing flow to the peripheral circulation and/or to organs such as the kidney. Whilst most healthy babies at term may adapt without major consequences, for those born preterm or with their cardio-respiratory circulation already impaired there may be substantive consequences.

Cord milking (pinching the cord close to the mother and running the fingers towards the baby, usually several times) has been suggested for preterm births as a means to increase neonatal blood volume without deferring cord clamping[15]. Cord milking over-rides the infant’s physiological control of its own blood volume and blood pressure, however, and disrupts umbilical blood flow.

Over 20 years ago it was first suggested that restricting placental transfusion by immediate clamping for preterm babies might increase the risk of intraventricular haemorrhage[16]. Possible
mechanisms for this increase were suggested to be hypovolaemia, and/or increased fluctuation in blood pressure following the abrupt transition to a neonatal circulation.

**Systematic review: immediate versus deferred cord clamping**

The recently Cochrane Review of timing of cord clamping for preterm births [17] includes 15 trials, with 738 infants, recruited between 24 and 36 weeks gestation. In these trials immediate cord clamping ranged from 5-20 seconds, although several studies did not state the duration. Deferred clamping ranged from 31-120 seconds for births before 34 weeks, one study recruiting between 34 weeks and 36 weeks gestation used 180 seconds. The few studies that reported a rationale for how long to defer clamping said it had been a balance between allowing placental transfusion, and what was perceived as an acceptable delay in transferring the baby to the resuscitaire and providing neonatal care. One small trial (40 mother-infant pairs) compared cord milking with immediate cord clamping[15].

Many outcomes are reported by only a few studies, so there is potential for reporting bias. No trials reported outcome for the mother.

Thirteen studies (668 infants) reported infant death (largely death before discharge from hospital). Of those allocated deferred cord clamping 10/319 (3.1%) died compared with 17/349 (4.9%) allocated less placental transfusion (risk ratio (RR) 0.63, 95% confidence interval (CI) 0.31 to 1.28). No trials reported outcome at age two to three years. One small trial[18] reported neurodevelopment at seven months (corrected for gestation at birth). Of 72 children recruited, five (6.9%) had died and nine (12.5%) were lost to follow-up. There were no significant differences between the groups in Bayley II Mental Development Index and Psychomotor Developmental Index for the 58 children assessed.

Severe intraventricular haemorrhage (grade three and four) was reported in six trials (305 infants) with no clear difference between babies allocated deferred rather than immediate clamping (5/154 versus 7/151: RR 0.68, 95% CI 0.23 to1.96). Ten trials (539 infants) reported IVH (all grades) and deferred clamping was associated with a lower risk ratio (RR 0.59, 95% CI 0.41 to 0.85). Only two studies (71 infants) reported periventricular leukomalacia, insufficient evidence for any reliable conclusions.

Three trials (143 infants) reported mean temperature on admission to special care unit; there was no clear difference between the groups (mean difference 0.14, 95% CI -0.03, to 0.31). Respiratory distress syndrome was reported by three studies (115 babies), with no clear difference between the two groups (RR 1.16, 95% CI 0.89 to 1.50). Five trials (265 infants) reported ventilation (RR 0.97, 95% CI 0.71 to 1.31). Need for oxygen at 28 days after birth was reported by two trials (76 infants), with no clear difference between the groups (RR 0.48, 95% CI 0.15 to 1.59). Need for oxygen at 36 weeks' gestational age was reported by five trials (209 infants), again with no clear difference between the groups (RR 0.69, 95% CI 0.42 to 1.13). Chronic lung disease was not reported in any studies.

There was no clear difference in need for transfusion for low blood pressure (4 trials, 130 infants, RR 0.52, 95% CI 0.24 to 1.11, random effects). In the seven studies (392 infants) reporting blood transfusion for anaemia, the risk was lower for those allocated deferred clamping: 44/186 (24%) versus 5/206 (36%). RR 0.61 (95% CI 0.46 to 0.81).

There was no clear difference between the groups in treatment for patent ductus arteriosus (5 trials, 223 infants, RR 1.04, 95% CI 0.60 to 1.81). Necrotising enterocolitis was reported in five trials with a lower risk ratio associated with deferred clamping (241 infants, RR 0.62, 95% CI 0.43 to 0.90).

Peak bilirubin concentration was higher for infants allocated deferred clamping (7 trials, 320 infants, mean difference 15.01 mmol/l, 95% CI 5.62 to 24.40). There was no clear difference in phototherapy for jaundice in the three studies reporting this outcome (180 infants, RR 1.21, 95% CI 0.94 to 1.55). Exchange transfusion was not reported by any of the trials.
The review concludes that “to reliably compare strategies for influencing placental transfusion we need large high-quality trials, with sufficient power to reliably assess clinically relevant differences in important outcomes”.

**Initial care at birth for very preterm infants: at the bedside or at the roomside**

Initial neonatal care and stabilisation takes place on a resuscitare. Traditionally, this is at the side of the room, or in an adjacent room. Disadvantages of these locations are that they necessitate immediate cord clamping, and that often the woman and her partner are not able to see or touch their baby at birth\[19, 20\]. If cord clamping is deferred this should not mean that neonatal care is deferred. Strategies for providing neonatal care and stabilisation of the baby at the bedside have now been developed. Parents views following initial care at the bedside have been universally positive\[21\]. Evaluation of the views of clinicians is also positive, although there are initial issues around training, practical arrangements for preparing and moving the equipment, and making space at the bedside\[21\]. The experience of providing initial neonatal care at the bedside has been so positive that it is now part of standard care in some hospitals.

Deferring cord clamping should not delay neonatal care, rather neonatal care can be available at the bedside. Providing neonatal care for very premature infants at the bedside would allow the woman and her partner to share the first moments of their child's life\[22, 23\], if they wish to, and it is potentially a more family-centred approach. Family-centred care in neonatal units, with improved communication and involvement of parents in their baby's care, appears to benefit babies, is welcomed by parents\[10\] and is an NHS priority\[24\]. Providing neonatal care at the bedside has parallels with family presence during resuscitation of adults and children; which is preferred by families and appears to be beneficial\[25-29\].

**Current practice for timing of cord clamping at very preterm births**

In the UK, 57% of obstetricians report clamping the cord within 20 seconds for very preterm births \[30\]. Just 15% of midwives and 5% of obstetricians report that they routinely record when the cord was clamped in the medical notes. Guidelines for care during the third stage of labour make various recommendations, and it is often not clear how these should be applied to very preterm births. For example, the National Institute for Health and Clinical Excellence (NICE) recommends that active management of the third stage of labour for term births should include "early cord clamping"\[31\]. The World Health Organisation (WHO) recommendations for prevention of postpartum haemorrhage apply to all births. WHO recommends "the cord should not be clamped earlier than is necessary for applying cord traction in the active management of the third stage of labour. For the sake of clarity, it is estimated that this will normally take around 3 minutes. Early clamping may be required if the baby is asphyxiated and requires immediate resuscitation"\[32\]. This guideline also notes the low evidence base for these recommendations. In 2011, the Royal College of Obstetricians and Gynaecologists recommended "the cord should not be clamped earlier than is necessary, based on a clinical assessment of the situation. Delayed cord clamping (more than 30 seconds) may benefit the neonate in reducing anaemia, and particularly the preterm neonate by allowing time for transfusion of placental blood to the newborn infant". The Resuscitation Council recommendations for newborn life support state “Cord clamping should be delayed for at least 1 minute in babies who do not require resuscitation. Evidence is insufficient to recommend a time for clamping in those who require resuscitation\[33, 34\]. Most very premature babies will require resuscitation.

1.2 Why a trial is needed now

Preterm birth is the most important single determinant of adverse infant outcome in terms of: survival; quality of life; psychosocial and emotional impact on the family; and costs for health services. Current evidence is that for very preterm births timing of cord clamping, and other strategies to influence placental transfusion, may influence some measures of morbidity before discharge from hospital. But the trials are small and overall there is high risk of bias. The effects on more substantive outcomes and long term neurodevelopment remain uncertain. Assessing
alternative strategies for timing of cord clamping has been identified as a research priority by service users[35], researchers[36-39] obstetricians[30], midwives[30], neonatologists[40], NICE[31, 41], and the Royal College of Obstetricians and Gynaecologists[22]. Providing immediate neonatal care at the bedside is potentially a more family centred approach than providing immediate neonatal care at the side of the room.

Our primary hypothesis is that for children born before 32 weeks gestation immediate cord clamping is associated with higher death or neurosensory disability at two years of age (corrected for gestation at birth) than deferred cord clamping. A trial to test this hypothesis would need to be large and multicentre. This protocol is for a pilot trial to assess the feasibility such a study.

2 PILOT TRIAL OBJECTIVES AND PURPOSE

2.1 Objectives
The objective of the main trial will be to compare the effects of immediate cord clamping versus deferred cord clamping for very preterm births on outcome for the women and children. This pilot trial is to assess the feasibility of conducting such a trial in the UK by:

1. estimating the number of potential recruits in each centre
2. measuring recruitment rate
3. listing reasons for non-recruitment (medical, parental, logistic, other)
4. measuring the spectrum of gestational age and neonatal outcome among recruits
5. measuring compliance with the trial interventions, and assessing factors in non-compliance
6. measuring the completeness of data collection for main outcomes
7. recording views of parents on the randomisation and treatment procedures
8. measuring losses to follow up after discharge from hospital.

3 TRIAL DESIGN

3.1 Main trial outcomes
The primary outcome for the main trial will be death or neurosensory disability at age two years (corrected for gestation at birth).

Secondary outcomes for the baby will include: death, blood transfusion, intraventricular haemorrhage (grade 3-4), periventricular leukomalacia, hypothermia, respiratory distress syndrome, ventilation, necrotizing enterocolitis, treatment for hyperbilirubinemia, duration of hospital stay, neurosensory delay at age 2 years (corrected for gestation at birth).

Secondary outcomes for the mother will include postpartum haemorrhage, depression, and breast feeding/expressing. Outcomes for the parents will include qualitative psychosocial outcomes (e.g. perceptions of the child's illness and care, parenting stress, parent-baby bond) and views about participation in the trial.

3.2 Pilot trial outcomes
For this pilot trial to assess feasibility of the main trial, outcomes will be:

1. number of women recruited in each hospital
2. proportion of potentially eligible women recruited
3. reasons for non-recruitment (medical, parental, logistic, other)
4. spectrum of gestational age and neonatal outcome among recruits
5. compliance with the trial interventions, and reasons for non-compliance
6. completeness of data collection for main trial outcomes (see above)
7. views of women and their partners on recruitment, randomisation and the interventions
8. proportion lost to follow up after discharge from hospital, and reasons for loss to follow up
3.3 Pilot trial description
This pilot trial will be a pragmatic randomised trial comparing a policy of immediate clamping of the umbilical cord with a policy of deferred clamping. For deferred cord clamping, care for the baby will be provided at the bedside. For immediate clamping care will be either at the bedside or at the side of the room, at the discretion of the attending clinicians. In both cases the baby will receive the same care at birth, just in different places. The aim is to recruit at least 100-110 women for the initial feasibility phase in at least eight maternity units. Recruitment to the initial feasibility phase of the pilot trial will be for 12 months. After this initial phase recruitment will be extended until 31 December 2014. Follow up for the women is for 12 months, and follow up for the children is until age two years (corrected for gestation at birth).

3.4 Randomisation
Women will be randomly allocated in a 1:1 ratio to the two intervention groups. Sequence generation will be using computer generated random permutated balanced blocks of randomly varying size, created by the Nottingham Clinical Trials Unit in accordance with their standard operating procedure. Randomisation will be stratified by hospital.

Women who are eligible and have agreed to participate will be randomised using sealed consecutively numbered opaque envelopes. Envelopes will be in a Cord Trial ringbinder, and removed in consecutive order by tearing at the punch holes. Each maternity unit will keep a central log of all envelopes. On the front of the envelope will be a reminder to check eligibility criteria, and space to record the date, time, woman’s initials, her data of birth, and her estimated gestation. Once this information is complete, the woman will be considered to be randomised, even if the pack is not opened.

Inside the envelope will be a card with the allocated intervention, two stickers (one each for the woman’s and baby’s notes) and a Birth Record to record details of the birth and initial care at birth. This Birth Record is then filed in the baby’s hospital case notes.

3.5 Minimisation of bias
Allocation to the treatment group will be concealed until after the woman has been entered into the trial. This will minimise selection bias. Stratification by centre will minimise the potential for chance imbalance at trial entry.

Blinding of the intervention is not possible for this study. Neurodevelopment assessment of the child at age two years, corrected for their gestation at birth, will be blind to the treatment group. Potential for bias in the assessment of outcome will be minimised by the use of objective outcomes.

3.6 Pilot trial interventions
There is no consensus about the definition of immediate or deferred cord clamping, or about the optimal timing of cord clamping for very preterm birth. We have chosen our interventions based on current practice in the UK[30], the interventions reported in the trials included in the Cochrane review[37], consultation with neonatologists, and our work measuring the volume and duration of placental transfusion[11]:

The interventions are:
- immediate cord clamping: clamping the cord within 20 seconds.
- deferred cord clamping: clamping the cord after at least two minutes.

For deferred cord clamping, care for the baby will be provided at the bedside. For immediate clamping care will be either at the bedside or at the side of the room, at the discretion of the attending clinicians. In both cases the baby will receive the same care at birth, just in different places. For both allocated groups, whilst the cord is intact the baby should not be lifted above the level of the mothers’ abdomen.
Neonatal care will be the same for the two allocated groups, based on local unit policy and consistent with newborn life support guidelines[33, 34]. Standard equipment will be used for both groups according to local practice, this is likely to include plastic sheets or bags (depending on gestation and local practice), towels and any other equipment such as hats, warming mattress or overhead heaters, and saturation monitors.

For neonatal care at the bedside, babies will be placed onto a firm surface next to the mother’s bed or to the operating theatre table, with easy access to necessary equipment. This will be achieved either by moving the conventional resuscitaire alongside the woman’s bed (Schoonakker, personal communication) or by using a small specialised mobile trolley (for example the BASICS trolley[42]). For neonatal care at the side of the room, care and stabilization will be according to usual practice in that unit.

All other aspects of care will be at the discretion of the attending clinicians, including administration of a prophylactic uterotonic drug.

3.7 Duration of participation
Follow up for the women will be for 12 months, and for the children until they are two years old, corrected for gestation at birth. The end of the trial is defined as the “last child’s 2 year Follow Up”.

3.8 Stop-go criteria for proceeding to the main trial
These will be:
- recruitment is at least 50% of target at 12 months. But, if recruitment is below 80% of target, there will need to be clear and achievable strategies for overcoming identified barriers thereby improving recruitment
- at least 80% of women in each group receiving the intervention to which they had been allocated or, if compliance is initially poor, this level of compliance is achieved during the final 6 months of recruitment
- median difference between the two groups in timing of cord clamping is at least 45 seconds

3.9 Compliance with interventions
Time of birth and time of cord clamping will be recorded for both treatment arms. If the cord is not clamped according to the allocated intervention, the reason will be recorded. Neonatal care at the place of birth will be documented. Reasons for non-compliance will be discussed with local clinicians and every effort made to remove obstacles to good compliance.

Compliance will be assessed by an independent observer for a randomly selected sample of participants.

3.10 Maintenance of randomisation codes and procedures for breaking code
In this trial it will not be possible for the participants or the labour ward staff to be blind to which intervention has been allocated. A procedure for breaking the code is therefore not necessary.

Every effort will be made to ensure neurodevelopment assessment of the child is blind to the allocation. The assessor will not have access to this information, and parents will be asked not to reveal it.

3.11 Source data
Information required at randomisation will be recorded on the randomisation envelope at trial entry (see 3.4 above). Demographic details will be collected later from the medical notes. Compliance with the allocated intervention will be based on timing of cord clamping and time of birth collected on the randomisation pack.
Outcome data for the women will be the medical notes, and the pilot trial questionnaires. For the children, outcome data will come from the medical notes and the Ages and Stages Questionnaire (ASQ) [43]. For families recruited between 01 March 2013 – 28 February 2014, outcome data will also be collected from the Parent Report of Children’s Abilities – Revised (PARCA-R) [44-46] and the Bayley Scales of Infant Development [47].

To allow contact for the follow up assessment contact details for the women and children will be sent to the central co-ordinating team at the Nottingham Clinical Trials Unit. To facilitate maintaining contact with the families, women will also be asked to provide contact details with other relevant relatives, for example grandparents. NHS numbers will also be supplied, so that they can be used for ‘flagging’ with the NHS Information Centre (see below). This will allow identification of deaths and movement out of the NHS before the family is contacted for follow-up. All identifiable data will be held securely and separately from the trial data. Access will be restricted. All trial data will be anonymised by use of unique participant trial numbers. The chief investigator, Professor Lelia Duley, is the custodian of the data. Participants have the right to revoke their authorisation for the use of personal information.

4 SELECTION AND WITHDRAWAL OF TRIAL PARTICIPANTS

4.1 Inclusion criteria
Women will be eligible for the study if they are expected to have a livebirth before 32 weeks gestation, regardless of mode of birth or whether cephalic or breech presentation.

4.2 Exclusion criteria
Exclusion criteria are:
- Monochorionic twins (from an ultrasound scan) or clinical evidence of twin-twin transfusion syndrome
- Triplets or higher order multiple pregnancy
- Known congenital malformation

4.3 Participants who withdraw
Women who give informed consent but decide later that, for whatever reason, they do not wish to be entered into the trial will not be randomised. Women who give informed consent, but do not give birth before 32 weeks will not be randomised.

Withdrawal between randomisation and birth is unlikely, as these events should be close together. If this does happen, care will be according to their preference or the preference of their attending clinician. Women will be analysed in their allocated group as “intention to treat” regardless of whether they received the intervention.

Women cannot withdraw from the trial intervention after the birth, as the intervention will be complete. Women who withdraw after discharge from hospital will not be contacted further. If a woman does withdraw, the date and reason for withdrawal (if available) will be recorded. Data for women who withdraw will be included in the analysis, unless they request that their data is not used.

If a family is lost to follow up, all reasonable attempts will be made to contact them in order to complete the trial assessments.

4.4 Managing and replacing participants who withdraw from the trial early
We anticipate minimal withdrawals from the trial, and this will be one of the outcomes assessed in this feasibility pilot. Women who withdraw will not be replaced.
5 TRIAL PROCEDURES

5.1 Trial entry and recruitment

General information about the trial, including posters and a summary information leaflet, will be available at all antenatal clinics, and on antenatal wards. Other strategies to help raise awareness of the trial, such as a short video for use in antenatal clinics and short talks with a question and answer session, will be developed and evaluated as part of this pilot study. To avoid causing unnecessary anxiety, this information will make clear that women would only be approached about the study if they were considered likely to give birth before 32 weeks gestation, and that this occurs for only around 1 in 70 births. If a woman requests not to be approached to participate, this wish will be respected and recorded in the medical notes. Women who ask for more information may be offered the parents’ information leaflet.

Women who are in hospital, in a day care unit, or a high risk antenatal clinic, and are expected to give birth before 32 weeks gestation, will be given the parents’ information sheet. They will have the opportunity to discuss this with their family and to ask any questions they might have. Clinical staff, including midwives, obstetricians and neonatologists, will be informed about the trial, so they are able to discuss it with potentially eligible women and their partners.

Whenever possible, women will have at least 12 hours to consider participation. If they are willing to participate they will have eligibility criteria checked, and be asked to provide written informed consent. If the woman does not wish to participate, she will not be required to give a reason. Clinical care for the woman and her baby will not be influenced by whether or not she agrees to participate. A log will be kept of potentially eligible women not approached to give consent, women who decline participation, and any other reasons for non-participation (if available).

When a woman who has given consent is in established labour, or being prepared for caesarean section, the attending clinician will check eligibility again (flowchart 1). If she remains eligible, the woman will be asked if she is still willing to participate. The clinician will record in her hospital notes that consent was confirmed before randomising the woman. This randomisation close to the time of birth will help ensure women who are randomised do give birth before 32 weeks gestation. Nevertheless, if women are randomised but give birth after 32 weeks gestation they will remain in the analysis, which will be by intention-to-treat.

Preterm birth can sometimes be rapid and unexpected. For a few women, birth may be so rapid that there is not sufficient time to discuss the study in detail and secure written informed consent. As this group of women and their babies are high risk for poor outcome, it is of particular importance that they are offered the opportunity to participate in the trial, rather than being excluded. As outlined above, all women will have had access to information about the trial whilst attending antenatal clinics. If there is not sufficient time to discuss the study and obtain written informed consent, women will be approached to give oral assent only if the attending clinicians consider it appropriate. This process is in line with Clinical Governance Advice for valid consent for research while in labour from the Royal College of Obstetricians and Gynaecologists [48]. After giving a brief summary of the study, with the opportunity to ask any questions, the woman will be asked if she is willing to be recruited. If she says yes, she will be randomised. If she does not give oral assent she will not be recruited. How long will be required for oral assent will depend on factors such as how much the woman already knows about the study, and her knowledge and wishes about care during the third stage. If the woman is recruited, she will be approached before discharge from hospital to give written informed consent for access to her medical records, and for participation in the trial follow up (flowchart 2). This strategy for recruitment is endorsed by the National Childbirth Trust and Bliss, the special care baby charity. Representatives of both these organisation are co-investigators on the trial and have contributed to development of this protocol, including the procedures for consent, oral assent and recruitment.
5.2 Treatment of participants

Once in the trial, women will either have the cord clamped within 20 seconds or the cord will be clamped after at least 2 minutes. The time of birth and the time of cord clamping will be recorded using the same clock. For deferred cord clamping, care for the baby will be provided at the bedside. For immediate clamping care will be either at the bedside or at the side of the room, at the discretion of the attending clinicians.

Whilst the cord is intact the baby can be at the level of the placenta, effectively on the bed between the woman’s legs if she has had a normal birth and is semi-recumbent. If the woman gave birth on all fours she should be encouraged to adopt a semi-recumbent position and the baby placed between her legs. For a vaginal instrumental birth the baby should be no higher than the woman’s abdomen. For a Caesarean section, the baby should be no higher than the anterior thigh. All other aspects of care will be at the discretion of local clinicians, including strategies for keeping the baby warm at birth.

If neonatal care is at the bedside, women will be able to see and usually touch their baby, if they wish. For Caesarean section with epidural anaesthesia, women will be offered the opportunity to see their baby, if they wish (this may be possible either by leaving a gap in the surgical drapes or by use of a mirror). Training for all the clinicians in providing care at the bedside will include encouraging them talk to the parents, to support them and to explain what is happening.

If the allocated intervention is not given, the reason will be recorded. For example, the attending clinician may decide not to comply with the allocated intervention, and women have the right to request at any time that the timing of cord clamping is changed. Women and their babies remain in the trial regardless of whether or not they received the allocated intervention.

Training for clinicians will be provided for both interventions. Compliance with the allocated intervention will be checked on a random sample at each centre, by independent observation. Information about other aspects of care during the third stage of labour that might influence placental transfusion, such as position of the baby whilst cord intact and timing of administration of the uterotonic drug, will also be collected.

5.3 Participant follow-up

The follow up assessments are summarised in table 1. At discharge from hospital, outcome data for the women and babies will be collected from the medical notes. Within 2-3 months after the birth, women will also be asked to complete a brief questionnaire. If their baby is still in hospital, they may be given this questionnaire by the research nurse. Otherwise it will be posted to them with a stamped addressed envelope.

When the child is one year old, a birthday card will be sent along with a questionnaire about the woman’s own health. A stamped addressed envelope will be provided to return questionnaires. If the child dies before their first birthday, the mother will remain in follow up as long as she is in agreement with this. At the child’s second birthday, corrected for gestation at birth, the family will be contacted for the 2 year follow up.

Families recruited into the trial between 01 March 2013 and 28 February 2014, will be contacted to arrange a neurodevelopment assessment for their child. Four weeks before the child’s second birthday, corrected for gestation at birth, the family will be sent the Ages and Stages Questionnaire (ASQ) by post, and asked to complete and return this before the assessment. A stamped addressed envelope will be provided to return the questionnaire. The neurodevelopment assessment will use the Bayley Scales of Infant Development III, and will be conducted by a trained practitioner either at home or in the clinic, whichever is preferred by the family. The assessment usually takes between one and a half two hours. Parents will also be offered the opportunity to complete the Parent Report of Children’s Abilities – Revised (PARCA-R) at the neurodevelopmental assessment. This usually takes between 30-45 minutes to complete.
Families recruited to the trial from 01 March 2014 onwards will be sent the Ages and Stages Questionnaire (ASQ) by post approximately at around the child’s second birthday, corrected for gestation at birth. A stamped addressed envelope will be provided to return the questionnaire.

For all questionnaires, a reminder will be sent after two weeks. If there is no response after a further two weeks the family will be contacted by phone to find out whether they received the questionnaires, and to offer the opportunity of completing the questionnaire by phone. If no telephone number is available a second reminder will be sent by post.

Flagging with the NHS Information Centre
All women and their babies recruited in the trial will be ‘flagged’ after discharge through the Medical Research Information Service, at the NHS Information Centre. Information from the NHS Information Centre may be used to help contact participants, and to check their health status. This will avoid causing unnecessary distress to the family, as it will avert inappropriate contact if the baby dies after discharge from hospital. It will also reduce losses to follow up.

6 ADVERSE EVENTS
In this study the key participants are babies born very preterm, who are high risk for adverse outcome due to being born too soon. The study is comparing two different policies for care at birth, to assess their comparative effects. Adverse events that could be influenced by the trial interventions are therefore outcomes for the study. Data on these events will be recorded on the case report forms.

6.1 Serious adverse events
Although neonatal or infant death is one of the outcomes for this study, death before discharge from hospital will be considered as a serious adverse event (SAE). Any unexpected and serious adverse event, for either the mother or the baby, considered to be potentially related to the study interventions will also be reported as a SAE. Any SAE that is not a death will be followed until there is resolution or the event is considered stable.

All SAEs will be reported to the Chief Investigator within one working day. The Chief Investigator will submit, every six months for the duration of recruitment to the trial or on request, a safety report to the Data Monitoring Committee which will include all reported SAEs.

7 STATISTICS AND DATA ANALYSIS
7.1 Estimated sample size
For this feasibility pilot study, we plan to include eight large maternity hospitals and recruit for one year. There are a total of 43,600 livebirths per year at these eight hospitals (average annual livebirths per unit 5-6,000). In the UK, 1.4% of livebirths are before 32 weeks gestation, we therefore expect 610 potentially eligible births and anticipate recruitment of between 100 and 110 women (16-18% accrual). If more than eight hospitals wish to participate, we will include them on the agreement we do not have site-specific funding to support their participation. Inclusion of such sites would give further evidence of feasibility of conducting the study within the Comprehensive Local Research Network.

In October 2013 it was agreed within the CORD Pilot Trial DMC and TSC meetings that recruitment to the pilot trial should be extended to run into the start of the main trial. This would allow clinicians in the current eight pilot study sites to avoid losing equipoise regarding the timing of umbilical cord clamping. Recruitment will be extended from 01 March 2014 until 31 December 2014, by which time a decision regarding the funding for the main trial should be definite.
For this study there should be no loss to follow up before discharge from hospital. For the questionnaire at six weeks we anticipate minimal loss to follow up (2%), as many infants will still be in hospital, and so parents will be asked to complete the questionnaire when they visit. At twelve months we anticipate 10% loss to follow up, and at two years 15%. Strategies to minimise losses to follow up will include regular contact with the family, for example thanking them for participation, birthday cards, and updating newsletters.

7.2 Analysis plan

Demographic and other baseline data at trial entry will be summarised using descriptive statistics (number and percentage, mean and standard deviation, median and inter quartile range (IQR)) as appropriate, by allocated group. All analyses will be according to the allocated group, i.e. by intention-to-treat.

Main trial outcomes: As this is a feasibility pilot trial there will be no formal test for efficacy. Nevertheless, data on the primary and secondary outcomes proposed for the main trial will be presented along with any missing data (number, percentage). Any unexpected SAEs reported will be described.

Pilot trial outcomes: The number of potentially eligible women at each centre will be reported, with the number recruited and reasons for non-recruitment (medical, parental, logistic, other, not known). Women recruited following oral assent will be described, along with the proportion who subsequently consented to participation in follow up and access to their data. The spectrum of gestational age at recruitment (range, median and IQR), and neonatal outcome for infants recruited will be described (number, percentage).

Compliance with the trial interventions will be summarised based on: number (percentage) who received the allocated intervention; median (IQR) for the difference in time of cord clamping between the allocated groups; position of the baby whilst the cord was intact per protocol (number and percentage). Reasons for any non-compliance with the allocated intervention will be listed (number, percentage). Neonatal care provided at birth will be described, along with whether at the bedside or at the side of the room (number, percentage). As outlined above, missing data for the main trial outcomes will be described (number, percentage).

Analysis of the views of women and their partners of participation in the trial will use methods described in detail elsewhere [49]. Factors that might influence parents experiences will be pre-specified as primary variables (death of the baby, allocated group) and secondary variables (maternal age at recruitment, gestation at recruitment less than 30 weeks, whether oral assent consent was used, severe post partum haemorrhage, postnatal depression, length of stay in special care baby unit longer than six weeks, and need for a reminder to complete the questionnaire).

The proportion of women and children lost to follow up after discharge from hospital will be reported at six weeks, one year and two years, along with reasons for the loss to follow up (if known).

No formal interim analysis is planned for this pilot study. Data will be monitored for safety only, in strict confidence, by the independent Data Monitoring Committee who will report to the Trial Steering Committee. The trial may be stopped due to a change in opinion of the research ethics committee; safety concerns of the Trial Steering Committee; or concerns about the trial conduct at the discretion of the sponsor.

Further details of the analysis will be supplied in a Statistical Analysis Plan to be finalised before database lock.
8 DIRECT ACCESS TO SOURCE DATA/DOCUMENTS
Direct access will be granted to authorised representatives from the sponsor as requested for trial-related monitoring and audit.

9 QUALITY CONTROL AND QUALITY ASSURANCE PROCEDURES
The trial will be conducted in compliance with the current revision of the Declaration of Helsinki (last amendment October 2008), with relevant regulations, and with MRC Guidelines for Good Clinical Practice in Clinical Trials (1998) which is based on ICH guidelines for GCP (CPMP/ICH/135/95) July 1996.

Compliance with the trial protocol will be ensured by a number of procedures:

9.1 Site start-up and training
Before trial recruitment begins, a meeting for the Principal Investigators, neonatologists and research midwives will be organised with workshops to discuss protocol issues, the trial interventions and related clinical issues, data collections issues, and trial procedures.

Each hospital will have a trial start-up visit, including training in the trial procedures, before the first woman is recruited. Sites will have at least one follow up visit within the first six months of recruitment, to ensure adherence to the protocol and to identify any specific site issues. Midwife trial days will be held for the research midwives involved in the trial to ensure that they are fully aware of issues such as consent, compliance with the protocol, data collection, and changing regulations.

Six months after recruitment begins, a second meeting for the Principal Investigators, neonatologists and research midwives will be organised to assess progress towards the pilot trial objectives, to discuss any problems that have been encountered, and to share experiences between sites.

9.2 Data collection and processing
Data will be collected using specific Cord Pilot Trial data collections forms. Processing of trial data and monitoring for consistency, validity and quality will be done as data accumulate by the Nottingham Clinical Trials Unit. Screening will include computerised checks for out-of-range data, and cross-checks for conflicting data within and between data collections forms. Missing data and data queries will be referred promptly back to the recruiting site for clarification.

9.3 Monitoring
Trial monitoring will be by central statistical monitoring combined with site visits. Central statistical monitoring will be used to monitor patterns of recruitment at sites, reasons for non-recruitment of potentially eligible women, characteristics of women recruited, gestation at recruitment, time of recruitment, etc. It will also be used to assess compliance with the protocol, which may include checking measures of eligibility and compliance with the trial interventions.

Based on assessment of data processing and central statistical monitoring, the Chief Investigator and Trial Statistician will decide if any further action needs to be taken.

When site visits are performed, a random sample of participants will have their data monitored at source (Source Document Verification). Any major discrepancies or concerns at a site visit would trigger a more extensive audit of trial data at that site.

9.4 Archiving
Data and all appropriate study documentation will be stored for a minimum of 10 years after completion of the trial, including the follow-up period. The trial master file and trial documents held by the Chief Investigator on behalf of the sponsor will be archived in secure archive facilities at
Nottingham University Hospitals NHS Trust. This archive will include all trial databases and associated meta-data encryption codes.

10  TRIAL MANAGEMENT

Day-to-day management of the trial will be the responsibility of the Trial Management Group. The Trial Management Group will report to the independent Trial Steering Committee. An independent Data Monitoring Committee will monitor safety of participants, and will report to the Trial Steering Committee. Trial co-ordination will be through the Nottingham Clinical Trials Unit (NCTU).

10.1 Trial Management Group
The Trial Management Group (TMG) will include the Chief Investigator, Study Clinical Neonatologist, NCTU Senior Trial Manager, Study Trial Manager, Trial Statistician, and other project staff. This group, based at the NCTU, will meet regularly, at least every four weeks.

10.2 Trial Steering Committee
The independent Trial Steering Committee (TSC) will provide oversight of the trial. It will meet (in person or by telephone conference) prior to commencement of the trial, and then at regular intervals until completion (at least annually). Specific tasks of the TSC are:

- to approve the trial protocol
- to approve necessary changes to the protocol based on considerations of feasibility and practicability
- to receive reports from the Data Monitoring Committee
- to resolve problems brought to it by the co-ordinating centre and TMG
- to ensure publication of the trial results
- to advise on whether the main trial would be feasible

10.3 Data Monitoring Committee
An independent Data Monitoring Committee (DMC) will be established. As discussed above no interim analysis is planned for this pilot trial, and so the role of the DMC for this feasibility study is to assess safety only. The DMC will receive safety reports every six months, or more frequently if requested. They will report their assessment to the chair of the TSC.

Collaborators, and all others associated with the trial, may write through the trial office to the DMC, to draw attention to any concern they may have about the trial interventions, or any other relevant issues.

10.4 Principal investigators
Each participating hospital will identify a Principle Investigator. The Principle Investigator (or his/her nominee) will be the local co-ordinator for that site, whose responsibilities will be to:

- be familiar with the trial protocol
- liaise with the Trial Co-ordinating Centre at the NCTU
- ensure that all site staff involved in the care of potentially eligible women are informed about the trial and have received requisite training
- ensure that the processes for recruiting eligible women, including easy availability of parent information, are in place; monitor their effectiveness and discuss reasons for non-recruitment with relevant staff
- notify the Trial Co-ordinating Centre of any serious adverse events
- make data available for verification, audit and inspection, as necessary
- ensure that confidentiality of all information about trial participants is fully respected
11 ETHICS

11.1 Approvals
The Chief Investigator will obtain approval from the Research Ethics Committee, which will be submitted for Site Specific Assessment (SSA) at each participating NHS Trust. The Chief Investigator will require a copy of the SSA approval letter before accepting participants into the trial.

All subsequent amendments to the protocol and associated documents will be submitted for approval prior to their implementation. The Chief Investigator will provide reports to the ethics committee at the intervals stipulated in the ethics committee guidelines.

Source documents shall be filed at the local site and may include but are not limited to consent forms, current medical records and CRFs. Only trial staff listed on the delegation log shall have access to the trial documentation other than the regulatory requirements listed above.

11.2 Participant confidentiality
Confidentiality of all participant information will be maintained throughout the trial. Each participant will be assigned a unique trial identification number, allocated at randomisation. This number will be used for data collection forms, other trial documents, and the trial database. Trial documents and the trial database will also use participants initials (of first and last names separated by a hyphen or a middle name initial when available) and date of birth (dd/mm/yyyy).

Data collection forms will be treated as confidential documents, and held securely. The Principal Investigator at each site will make a separate confidential record of the participant’s name, date of birth, local hospital number, NHS number, and participant trial number, to permit identification of all participants enrolled in the trial. To facilitate follow up, the address and telephone number for all participants will be sent to the Trial Co-ordinating Centre at the NCTU after they are discharged. This information will be stored securely and separately to the anonymised trial data. Access to all data will be restricted to those personnel approved by the Chief or local Principal Investigator, and recorded on a delegation log.

12 DATA HANDLING AND RECORD KEEPING

All trial data will be entered on a trial specific database with participants identified only by the unique trial number, date of birth, and initials. The database will be developed and maintained by the trial coordinating centre at the NCTU. Access to the database will be restricted and secure. As discussed above, data quality and compliance with the protocol will be assessed throughout the trial by central statistical monitoring and site visits.

For the follow up phase, identifiable information about participants will be held in a separate database to the trial anonymised data. Access to this information will be restricted to those involved in the follow up phase, as authorised by the Chief Investigator.

13 FINANCING AND INDEMNITY

This pilot trial is funded through the NIHR Programme Grant for Applied Research: Improving quality of care and outcome at very preterm birth (RP-PG-0609-10107).

Nottingham University hospitals NHS Trust will act as the main sponsor for this trial. Delegated responsibilities will be assigned to the NHS trusts taking part in this trial. Standard NHS Indemnity applies.
14 PUBLICATION POLICY

14.1 Reporting, dissemination and notification of the results
Trial results will be published in a peer reviewed journal. Reporting will be in compliance with CONSORT [50, 51] recommendations. Results will be made available to participants through a newsletter (unless they state they do not wish to receive this), and will also be publicised through NCT and BLISS (co-investigators for the trial) and where possible in the local press and media.

14.2 Policy for publication and authorship
The pilot trial results will be published by named members of the trial team, on behalf of the Cord Pilot Trial Collaborative Group. Members of the collaborative group will be listed in the publication, based on contributorship. Any secondary publication may be published by named individuals, but with appropriate acknowledgement of the collaborative group.

15 REFERENCES

10. POPPY Steering Group, Family-centred care in neonatal units. A summary of research results and recommendations from the POPPY project. 2009, London: NCT.


42. Weeks, A.D., M. Peake, and W. Yoxall, The Bedside Assessment, Stabilisation and Initial Cardiorespiratory Support (BASICS) trolley: enabling neonatal resuscitation with an intact cord. in RCOG World Congress. 2013: Liverpool.
Appendix 1. Principal Investigator Declaration

Principal Investigator Declaration
I confirm I have read and understood this protocol and I agree to conduct the study in accordance with the protocol.

Principal Investigator: (name) ______________________________________________

Centre name: _____________________________________________________________

Signature: _______________________________________________________________

Date: ____________________________